Peritoneal carcinomatosis is detected in 10-40% of patients with "first look" peritoneal tumors. Median survival after chemotherapy is generally 2-6 months. Use of cytoreductive surgery and intraoperative intraperitoneal chemohyperthermic perfusion (ISHTP) improves the end results significantly. The study included 45 cases of surgery: gastric cancer (15), ovarian and cervical carcinoma ('17), colorectal cancer (8) and miscellaneous cancers involving advanced peritoneal carcinomatosis (5). ISHTP procedure was carried out immediately after cytoreductive surgery including peritonectomy (Sugarbaker). Postoperative complication and lethality frequency was 37.7 and 22.2%, respectively; mean survival--17 months. Eight patients have survived without signs of relapse; three of them--for more than 2 years. Cytoreductive surgery plus ISHTP protocol for peritoneal carcinomatosis increases survival time 3-fold and improves quality of life.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cytoreductive surgery
16
peritoneal carcinomatosis
16
surgery intraoperative
8
surgery
5
peritoneal
5
[combined cytoreductive
4
intraoperative hyperthermic
4
hyperthermic chemo-perfusion
4
chemo-perfusion peritoneal
4
carcinomatosis
4

Similar Publications

Background: Prediction of open-close and long-term outcome is challenging in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prognostic scores often include factors not known at baseline. Therefore, we aimed to analyze whether patterns of preoperative tumor markers could aid in prediction of open-close surgery and outcome in patients with pseudomyxoma peritonei (PMP) or colorectal peritoneal metastases (PM).

View Article and Find Full Text PDF

Background: Hematologic changes after splenectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) can complicate postoperative assessment of infection. This study aimed to develop a machine-learning model to predict postoperative infection after cytoreductive surgery (CRS) and HIPEC with splenectomy.

Methods: The study enrolled patients in the national TriNetX database and at the Johns Hopkins Hospital (JHH) who underwent splenectomy during CRS/HIPEC from 2010 to 2024.

View Article and Find Full Text PDF

Introduction: Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) can improve survival for patients with peritoneal surface malignancy. Completeness of cytoreduction correlates with prognosis. The role of gastrectomy in these patients is not well described.

View Article and Find Full Text PDF

SummaryWe report a case of small cell carcinoma of the ovary, hypercalcaemic type, a rare and aggressive form of ovarian cancer, causing an acute kidney injury. A woman in her mid-30s presented with a large pelvic mass and abdominal distention, this was associated with rapidly deteriorating renal function, which did not improve with standardised kidney injury treatment. There was a high suspicion of ovarian cancer.

View Article and Find Full Text PDF

Novel technique and outcomes of umbilical reconstruction during cytoreductive surgery; a multi-centre study.

Tech Coloproctol

January 2025

Peritonectomy and Liver Cancer Unit, Department of Surgery, St George Hospital, Kogarah, NSW, Australia.

Background: The goal of cytoreductive surgery for peritoneal malignancy is to remove all macroscopic disease, which occasionally requires the excision of the umbilicus. While the absence of the umbilicus can be aesthetically undesirable for patients, umbilical reconstruction is rarely performed due to the perceived complexity and increased risk of wound infections (Sakata et al. in Colorectal Dis 23:1153-1157, 2021).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!